OCS Oaktree Specialty Lending: EV/EBITDA Multiple

Strict regulation of ophthalmological product delivery ensures research stability, yet military conflicts create risks for component supplies and patent protection. Financial support helps companies implement innovative transport. The EV/EBITDA multiple of Oaktree Specialty Lending (OCS) demonstrates market value relative to operating profit, with 0.00 serving as the final level marker.

OCS Oaktree Specialty Lending: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/14/2026

Metric breakdowns and analytics for Oculis Holding AG (OCS)

- stock price and consensus target price:

Stock Quotes oculis.com|OCS - Average Forecast Price

- company stock capitalization data:

Market Capitalization Oculis Pharma|OCS - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Oculis|OCS - Book Valuation of Business|Market Value to Book Value Ratio oculis.com|OCS - Company Assets

- debt and liquidity data:

- business earnings and investment ratios data:

OCS - Company Net Income|Projected Future Earnings Oaktree Specialty Lending|OCS - Market Cap to Earnings|Projected Price to Earnings Oaktree Specialty Lending|OCS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oculis Pharma|OCS - Operating income before deduction of amortization|Earnings per share for the last twelve months Oculis|OCS - Earnings per one share for the last 12 months|Quarterly EPS earnings growth oculis.com|OCS - Earnings per share growth rate in current year|Earnings growth forecast for next year Oaktree Specialty Lending

- sales volume and revenue indicators:

OCS - Company Sales|Projected Sales Volume Oculis Holding AG|OCS - Price-to-Revenue Coefficient|Forward P/S Multiple Oculis Pharma

Fundamental company analysis:Oculis Pharma (OCS)

Diversification of clinical developments in ophthalmology reduces regulatory risks for Oaktree Specialty Lending (OCS), although it necessitates strict control of the debt load. An analysis of the business's historical EV/EBITDA multiple allows for a comparison of the company's enterprise value against its operating profit, helping investors identify undervaluation points and avoid value traps while searching for a local bottom on the chart.

Competing companies

Alcon Vision - Enterprise Value to EBITDA Ratio|Bausch Health (BLCO) - Company Value to EBITDA|Glaukos Corporation - EV/EBITDA Multiple|Company Value to EBITDA apellis.com|Belite Bio Corp (BLTE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OCUL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Company Value to EBITDA Viridian Corp VRDN|EV/EBITDA Multiple LENZ|EV/EBITDA Multiple eyepointpharma.com (EYPT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kodiak Sciences KOD|EV/EBITDA Multiple Aldeyra Therapeutics Inc. ALDX|KALA: Enterprise Value to EBITDA Ratio|Opus Genetics Inc - Enterprise Value to Operating Income Before Depreciation Ratio|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Adverum Biotechnologies, Inc. - Business Value to Operating Income Before Depreciation|OTLK (Outlook Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Clearside Biomedical Inc CLSD|EV/EBITDA Multiple NBY|KPRX - Company Value to EBITDA|Alimera Sciences, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EYEN|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Ocuphire Pharma Inc OCUP|Opthea Ltd. (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization